Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bicara Therapeutics Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,855 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 12,500 · Balance 142,355 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Row 2 · 2026-08-10 · Sale · Disposed 12,500 · Balance 129,855 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2033-04-05 | Direct | 26,336 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 12,500 · Balance 26,336 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2025 Filed Oct 8, 2025 21:33 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 6,514 | $3.79 | $24,686.76 |
DisclosureSEC source: 0002034668-25-000004 · wk-form4_1759959228.xml · nonDerivative · entry 1 Hyep Ivan · CIK 0002034668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.